Literature DB >> 35535123

Incidental findings on a Tc99m-SESTAMIBI parathyroid scan post COVID-19 vaccination.

Mitchel A Muhleman1, Jorge D Oldan1, Amir H Khandani1.   

Abstract

We present a case of abnormal findings on a Tc99m-Sestamibi parathyroid scan, post COVID-19 vaccination. The patient is a 48-year-old female presenting for evaluation of hyperparathyroidism who received the mRNA-1273 Moderna (ModernaTX, Inc.) vaccine seven days prior to the scan. The patient is right hand dominant and reported no traumatic events, inflammation, infection, or extraneous use of the left arm. The patient did report "soreness" of the extremity starting approximately 24 hours post injection which continued to the time of the study. AJNMMI
Copyright © 2022.

Entities:  

Keywords:  COVID-19 vaccination; Tc99m-Sestamibi increased uptake

Year:  2022        PMID: 35535123      PMCID: PMC9077171     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  4 in total

1.  (99m)Tc-MIBI emboli in the lungs detected on SPECT/CT: a pitfall in parathyroid scan.

Authors:  Mustafa Aras; Tanju Yusuf Erdil; Tunc Ones; Fuat Dede; Halil Turgut Turoglu
Journal:  Clin Nucl Med       Date:  2014-02       Impact factor: 7.794

2.  Technetium-99m-MIBI scintigraphy in pulmonary tuberculosis.

Authors:  C Onsel; K Sönmezoglu; G Camsari; S Atay; S Cetin; Y T Erdil; I Uslu; A Uzun; B Kanmaz; H B Sayman
Journal:  J Nucl Med       Date:  1996-02       Impact factor: 10.057

3.  Unusual extracardiac findings detected on myocardial perfusion single photon emission computed tomography studies with Tc-99m sestamibi.

Authors:  Gonca Kara Gedik; Eser Lay Ergün; Mehmet Aslan; Biray Caner
Journal:  Clin Nucl Med       Date:  2007-12       Impact factor: 7.794

4.  Focal Pulmonary Uptake on 99mTc-Sestamibi Parathyroid Scintigraphy Due to Iatrogenic Microembolism.

Authors:  Ying Kou; Guohua Shen; Xiaohong Ou; Rui Huang; Anren Kuang
Journal:  Clin Nucl Med       Date:  2018-01       Impact factor: 7.794

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.